Hormonal
Tirzepatide is associated with a higher likelihood of gastrointestinal adverse events compared to other GLP-1 receptor agonists (semaglutide, dulaglutide, liraglutide, and exenatide).
If you take tirzepatide, expect gastrointestinal issues like nausea or vomiting more often than with other GLP-1 drugs. These are usually mild and go away, but they are the most common reason people stop the medication. Monitor your symptoms and report them.
The disproportionality analysis revealed that tirzepatide was associated with a higher likelihood of reported gastrointestinal AEs compared to GLP-1RAs. Specifically, tirzepatide exhibited a higher ROR (ROR: 1.35, 95 % CI: 1.47 - 1.23) and PRR (PRR: 1.16, 95 % CI: 1.26 - 1.06) than semaglutide...
Why this rating
Based on real-world pharmacovigilance data (EudraVigilance) using disproportionality analysis (ROR/PRR), which indicates signal strength but not causality.
Source
Safety profile of tirzepatide: A real-world pharmacovigilance analysis of EudraVigilance database
Atul Khurana et al. · Clinical Epidemiology and Global Health · 2024
DOI 10.1016/j.cegh.2024.101805
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →